be genetically defined and risk estimates of the frequency of islet autoantibodies in infancy are available.
We have shown previously that persistent autoantibodies often appear by the age of 2 years in offspring of parents with Type I diabetes [8, 9] . Recent genome-wide mapping has confirmed that HLA class II genes confer the greatest genetic risk for Type I diabetes [10±12] . In Caucasians Type I diabetes is strongly associated with HLA DR3 and DR4 alleles, and diabetes risk is particularly high for people with DR3/4 and DR4/4 genotypes which contain DQB1 alleles carrying non-Asp at residue 57 [13] . Taking advantage of the German BABYDIAB study where we prospectively followed such offspring from birth, we here analysed the frequency of HLA genotypes and their associated risk for early expression of islet autoantibodies in infancy in order to design primary prevention trials in susceptible people.
Subjects and methods
Subjects. Since 1989 we have conducted a prospective German multicentre study of infants followed from birth. The ªBABY-DIABº study of children from mothers or fathers with Type I diabetes investigates the temporal development of the responses of insulin autoantibodies (IAA), glutamic acid decarboxylase autoantibodies (GADA), the antibodies to the protein tyrosine phosphatase IA-2 (IA2A), and islet cell autoantibodies (ICA) at birth (cord blood) and at 9 months, 2, 5 and 8 years of age in all children [8, 9] . At 2 years of age, EDTA blood is requested from parents and the index child for HLA typing. Of 1429 children recruited at birth, 674 have reached the age of 2 years. Of these, 628 have participated in the 2-year follow-up visit (442 offspring had a mother with Type I diabetes, 171 offspring were offspring of a father with Type I diabetes, and for 15 offspring both parents were diabetic; median follow-up time from birth = median age: 3.3 years, range 1.5±8.7 years). There were 46 families (6.8 %) who refused to participate at the 2-year visit or were lost to follow-up because they had moved to an unknown address. We obtained EDTA blood samples for HLA typing from 477 (76 %) of 628 offspring (334 of a mother, 130 of a father and 13 of both parents with Type I diabetes, median follow-up time from birth = median age: 3.1 years, range 1.3±8.5 years). The major reason for not obtaining EDTA samples from 151 offspring was that the families did not always bring collection tubes which had been sent to each of them from our centre and EDTA tubes were not routinely available in the surgery of each family's general practioner. For those with islet autoantibodies samples for HLA typing could be obtained in subsequent visits. For ethical reasons, we could not ask families with antibody negative children for extra visits between 2 and 5 years of age to complete HLA typing but for offspring who reached 5 years of age missing EDTA samples were obtained at the 5-year follow-up visit. There were no differences in baseline characteristics (age, sex, relation to proband, diabetes duration and age of the parent) and clinical features (weight, height) between offspring who were HLA typed and those where no EDTA blood was available for HLA typing (z test).
HLA typing. We determined HLA class II alleles, HLA-DRB1, HLA-DQA1 and HLA-DQB1, using PCR-amplified DNA and non-radioactive oligonucleotide probes (sequencespecific oligonucleotide typing SSO). The HLA laboratory was not aware of antibody results prior to typing. Genomic DNA was isolated from fresh peripheral blood cells (EDTAblood) by the salting-out procedure described in the 11th workshop report [14] . After isolation, the DNA was resuspended in TE-buffer (1 mmol/l TRIS-HCl; 0.1 mmol/l EDTA, pH 8.0), adjusted to a final concentration of 250 mg/ ml and stored at ±20°C until used. Genomic DNA (1 mg) was amplified by PCR in a 100 ml reaction volume using 25 pmol of primers [14] , 20 nmol dNTP's, 2.5 units Taq Polymerase and buffer (10 mmol/l TRIS-HCl pH 8.3, 50 mmol/l KCl, 1.5 mmol/l MgCl 2 , 0.001 % gelatin). After a denaturation step at 94°C for 10 min, the samples were subjected to 33 cycles of PCR amplification in a Perkin Elmer Cetus 9600 thermocycler (Perkin Elmer RochØ Molecular Systems, NJ, USA) (DRB1generic: 94°C 1 min, 53°C 1 min, 72°C 1 min; DQA1: 94°C 1 min, 52°C 1 min, 72°C 1 min; DQB1: 94°C 45 s, 53°C 45 s, 72°C 45 s). Amplified DNA products were verified by agarose gel electrophoresis (1.2 %). For the dot blot hybridization the amplified DNA (2 ml) was spotted onto nylon membranes (Boehringer Mannheim, Mannheim, Germany) and hybridized with 15 DRB generic, 17 DQA and 20 DQB specific oligonucleotides, respectively [14] . The hybridized oligonucleotides 3 ¢ end labelled with digoxigenin-11±2 ¢,3 ¢-dideoxyuridine-5 ¢-triphosphate (Dig-11-ddUTP, Boehringer Mannheim) were detected using anti-dioxigenin-AP Fab fragments (Boehringer Mannheim) and made visible with the chemiluminescent substrate CSPD (Boehringer Mannheim) [15, 16] . The HLA-DRB1, HLA-DQA1 and HLA-DQB1 alleles were named according to the nomenclature of 1996 [17] . The alleles DQA1*03011 and *0302 were indistinguishable by SSO and were therefore referred to as DQA1*03. Also the alleles DQB1*0201 and *0202 were indistinguishable and were referred to as DQB1*02.
Classification of HLA genotypes. For analysis, offspring were grouped according to diabetes associated and non-associated HLA genotypes. Offspring with DR3 or DR4 were grouped as DR3/3, DR3/4, DR3/X and DR4/X where X is a non-DR3 and non-DR4 containing haplotype. In relevant cases, parents of offspring were also typed to confirm that their offspring were homozygotes for DR3/3 or DR4/4. Offspring who were DRB1*03/04 heterozygous with DQB1 alleles containing a non-Asp at residue 57 (*0302, *0304, *0305, or *0307) were sub-grouped to DR3/4(DQB1*57non-Asp); DR3/4 heterozygous offspring with a DQB1*0301, *0303, or *0306 allele were grouped to DR3/4(DQB1*57Asp). Similarly, DRB1*04/04 homozygous offspring with both DQB1 alleles containing a nonAsp at residue 57 (*0302, *0304, *0305, or *0307) were grouped to DR4/4(DQB1*57non-Asp). We grouped DR4/4 offspring with one or two DQB1 allele containing Asp at residue 57 to DR4/4(DQB1*57Asp). Children with DR2 and at least one DQB1*0602 allele were grouped into ªDRB1*02/ Y(DQB1*0602)º, including 19 children who had DR2/ 4(DQB1*0602/*57non-Asp) and 24 who had DR2/ 3(DQB1*0602/*0201).
Autoantibody determination. Autoantibodies to insulin (IAA), glutamic acid decarboxylase (GADA), the protein tyrosine phosphatase IA-2 (IA2A) and islet cells (ICA) were analysed as described previously [9] . The upper limit of normal was defined by the 99th centile of antibody levels in non-diabetic control children (IAA 50 nU/ml, GADA 13 units, IA2A 5 units, ICA 5 JDF-units; [9] ). Antibody assays were entered into the Antibody Proficiency Programme. The IAA assay achieved a specificity of 100 % and a sensitivity of 100 % (4th workshop), the GADA assay 100 % and 94 % (3rd workshop), the IA2A assay 100 % and 100 % (1st workshop) and the ICA assay 100 % and 67 % (9th workshop), respectively.
Classification of autoantibody status of offspring. In all 628 offspring sera were obtained for the determination of islet autoantibodies at birth, 9 months and 2 years of age. We classified 23 offspring as`autoantibody positive', defined as having at least one raised autoantibody specificity in at least two follow-up samples including the most recent serum sample. Typing for HLA was carried out in 22 of these. Of the 23 offspring with persistent autoantibodies 10 have progressed to diabetes. There were 592 offspring who had no raised autoantibodies in both their 9 month and 2 years sample and were classified as`autoantibody negative'. A further five had raised autoantibodies in one sample, but were negative in the most recent blood sample and were also included in the antibody negative group. In 448 of those 597 offspring HLA typing was available. In a further 8 offspring one or more autoantibodies were detected but no follow-up sample for confirmation of results was available at that time. These cases were neither included into the group of antibody`positive' nor antibody`negative' offspring and thus excluded from the analysis of the frequency of HLA genotypes and the life table calculation. None of these offspring has developed Type I diabetes to date and seven were HLA-typed and three carried the DR3/4(DQB1*57non-Asp) genotype.
Statistical analysis. Fisher's exact test was used to analyse differences between offspring from mothers and fathers with Type I diabetes and between offspring with and without islet autoantibodies. Kaplan-Meier life-table analysis was used to determine the cumulative development of the first antibody event. Follow-up started at birth and ended when antibodies were first detected or the day of the most recent blood sample. In children from mothers with diabetes, antibodies detected before age 0.5 years were excluded because of potential interference from antibodies acquired transplacentally, and in children from fathers with diabetes, IAA detected at birth were excluded because of potential artefact in IAA measurement in cord blood [9] . Antibody events were experienced at birth and at intervals between 0.5 and 1.5 years (9-month visit), 1.5 and 2.5 years (2-year visit) and 4.5 and 5.5 years (5-year visit). For all statistical methods the Statistical Package for Social Sciences (SPSS, Chicago, Ill., USA) was used.
Results
HLA genotype frequency in offspring of parents with Type I diabetes. Of 477 HLA typed offspring 34 (7.1 %) had the genotype DRB1*03/04(DQB1 *57non-Asp) and 24 (5.0 %) had DRB1*04/ 04(DQB1*57non-Asp) ( Table 1) . No significant difference in the frequency of HLA genotypes was seen between offspring from affected mothers or fathers.
HLA genotype and antibody development. By the age of 2 years 23 (3.7 %) offspring developed islet autoantibodies (Table 2) . Of these 15 were offspring from a mother with Type I diabetes, 6 from a father with Type I diabetes and for 2 children both parents were diabetic. The median age when the first antibody appeared was 1.5 years (range 0.6±2.4 years). Two offspring had IAA only, 4 offspring had 2 antibodies, 3 had 3 antibodies, and 14 had all four antibody specificities. Of the 22 who were HLA typed, 8 (36 %) had genotypes with DR3 and 17 (77 %) genotypes with DR4(DQB1*57non-Asp); 6 had the DR3/ 4(DQB1*57non-Asp) and 5 the DR4/4(DQB1 *57non-Asp) genotype. Table 3 compares the frequency of HLA DRB1/ DQB1 genotypes in offspring with and without islet autoantibodies. We found HLA DRB1*03 haplotypes in a similar frequency in offspring with (18 %) and without (15 %) islet antibodies. The frequency of HLA DRB1*04(DQB1*57non-Asp) haplotype was higher in offspring with islet antibodies (50 % vs 25 % in offspring without antibodies p < 0.01). Only genotypes with HLA DRB1*04(DQB1*57non-Asp) were more prevalent in offspring with islet antibodies. The frequency of the DRB1*03/04(DQB1 *57non-Asp) genotype was 27.3 % in offspring who had islet autoantibodies by 2 years of age compared with 5.5 % in offspring without these autoantibodies (odds ratio 6.3 [95 % CI 2.3, 17.5], p = 0.002). The frequency of DRB1*04/04(DQB1*57non-Asp) was 22.7 % in offspring with islet autoantibodies and 4.2 % in offspring without antibodies (odds ratio 6.6, p = 0.003). Together, 11 (50 %) offspring with islet autoantibodies had either the DR3/4(DQB1*57non-Asp) or DR4/4(DQB1*57non-Asp) genotype compared with 44 (9.8 %) offspring without islet antibodies (odds ratio 9.2 [95 % CI 3.8±22.4], p < 0.0001). No other genotypes, including DR3/3, DR3/4(DQB1*57Asp), DR3/ X, and DR4/X were associated with an increased antibody frequency. Genotypes containing DR2(DQB1 *0602)were absent in offspring with islet autoantibodies (0 % vs 15 %, p = 0.03). There were ten offspring with islet autoantibodies who developed Type I diabetes. All had multiple islet autoantibodies and two had the DR3/4(DQB1 *57non-Asp) and two the DR4/4(DQB1*57non-Asp) genotype. Autoantibody levels of IAA, GADA, and IA2A from birth until diabetes onset of these four offspring (numbers 4005, 2277, 1088, 3941) are shown in Fig. 1 .
Cumulative risk for autoantibody development with respect to HLA genotype. By life-table analysis, the cumulative risk of developing a first islet autoantibody event by 2 years of age was 20.0 % (95 % CI 9.4, 30.6) for offspring with either DR3/4(DQB1*57non-Asp) heterozygous or DR4/4(DQB1*57non-Asp) homozygous genotypes compared with 2.7 % (95 % CI 1.2, 
Discussion
In this study we analysed the association of HLA class II genotypes and the development of islet autoantibodies in early life in offspring of parents with Type I diabetes. Offspring carrying the high risk DR3/4(DQB1*57non-Asp) or DR4/4(DQB1*57non-Asp) genotypes had a sevenfold risk of developing islet autoantibodies by age 2 years. Of all offspring, 12.1 % had these genotypes and their cumulative risk of expressing raised autoantibody by the age of two years was 20 % compared with 2.7 % in offspring without these genotypes. Other genotypes were not associated with an increase in risk. Of 22 offspring with islet autoantibodies, 11 (50 %) had either the DR3/4 or DR4/4 genotype and 4 have already progressed to diabetes. The DR3/4 genotype has been shown previously to be associated with a more rapid progression to diabetes in islet autoantibody positive siblings of patients with Type I diabetes [18] . Moreover, in the DAISY study, 62.5 % of DR3/4 positive children with islet autoantibodies were diabetic before the age of 5 years [19] . Our data now indicate that not only the rate of progression could be accelerated in DR3/4 positive people with beta-cell autoimmunity but also the risk of developing this autoimmunity is remarkably enhanced in early life. Ascertainment with respect to HLA typing in this study was 76 % with a minor bias towards the antibody positive offspring and, therefore, the calculated 20 % islet autoantibody risk in offspring with high-risk HLA genotypes is possibly higher than the true risk. Based upon the 9.7 % prevalence of these genotypes in the HLA-typed autoantibody negative offspring, the true risk is estimated to be 16 % which is still considerably higher than autoantibody risk in offspring without the high-risk HLA genotypes. The risk of the development of islet autoimmunity in offspring appears to be more strongly associated with the presence of DR4 and diabetes susceptible DQA1/DQB1 non-Asp alleles since first- Table 2 ). Diabetes onset date is marked with an arrow. Horizontal lines indicate the upper limit of normal for IAA and IA2A (¾) and for GADA ( . . . . ) Fig. 2 . Kaplan-Meier life-table analysis: cumulative risk of islet autoantibody development in offspring from parents with Type I diabetes depending on the presence (¾) or absence (± ± ±) of a DR3/4(DQB1*57non-Asp) or DR4/4(DQB1*57non-Asp) genotype (p < 0.0001). 95 % confidence intervals are given. § indicates a non-Asp containing DQB1 allele ly, risk was not increased for offspring with DR3 in the absence of DR4, secondly, risk was increased for offspring with DR4/4(DQB1*57non-Asp) and thirdly, no offspring with DR3/4(DQB1*57Asp) or DR4/ 4(DQB1*57Asp) have developed antibodies. These observations also support the notion that DR4(DQB1*57non-Asp) is the HLA haplotype most strongly associated with Type I diabetes in childhood.
The observation that 20 % of DR3/ 4(DQB1*57non-Asp) and DR4/4(DQB1*57non-Asp) offspring of parents with Type I diabetes develop autoantibodies by two years of age may facilitate the design of intervention trials. The use of persistent antibody appearance rather than diabetes onset as the major outcome variable to determine efficacy of prevention strategies would considerably reduce trial length. This seems a feasible strategy for primary intervention trials since we have shown that the definition of antibody positivity used in this study is highly associated with subsequent progression to disease. It is likely that any primary intervention protocol for Type I diabetes should be started shortly after birth since islet autoantibodies can already be detected at 9 months of age. A major disadvantage of primary prevention trials is that without efficient genetic selection, the large majority of subjects enrolled will never develop disease and, as a consequence, the sample size required is enormous. Selection for risk on a genetic basis will both reduce trial size and concentrate on subjects with an increased risk of developing disease.
Based on the results of this study, it is possible to design a trial for the prevention of the appearance of diabetes-associated islet autoantibodies. In a cohort with a 20 % risk of developing islet antibodies, a trial aimed at detecting a 50 % reduction in antibody development with a power of 80 %, an alpha (p) of 0.05 and a 10 % drop-out rate would require 220 subjects in each arm. Selection of offspring with the DR3/ 4(DQB1*57non-Asp) genotype would include 7.1 % of all offspring of parents with Type I diabetes, including 27 % of those who develop persistent islet autoantibodies by 2 years of age. If a treatment and a placebo arm were used and a refusal to participate of 20 % assumed, a total of 7437 offspring of parents with Type I diabetes would need to be typed for HLA DR3 and 04 and subsequently DQB1*57non-Asp alleles. If offspring with DR4/4(DQB1*57non-Asp) genotypes were also included, the number of offspring requiring HLA typing would be reduced to 4364 and half of those who develop persistent islet autoantibodies by 2 years of age would participate. The HLA typing for DR4/4(DQB1*57non-Asp) is, however, less straightforward since generic typing for non-DR4 alleles must be carried out to exclude the DR4/X genotypes and parents may also require typing for DR4 to confirm they are DR4/4 homozygotes in relevant cases. A disadvantage of selection on a genetic basis is that potentially 50 % of children developing islet autoantibodies and diabetes do not express these high-risk genotypes (Table 2) and it cannot be assumed that any given therapy will be effective for all genotypes. It is our experience from the BABYDIAB study that as cord blood samples can be used for HLA typing and are relatively easy to collect typing at this time is preferable and avoids taking blood from the child which is painful or the use of mouth swabs. It should also be considered that recruitment of over 4000 offspring of parents with Type I diabetes is a major undertaking requiring multicentric or multi-national participation. Intervention therapies should, therefore, have a strong rationale and adequate validation prior to use in such trials.`Vaccination' trials with insulin or insulin peptides shortly after birth has been shown in animal models to successfully prevent disease [6, 7] . Similar vaccination' trials in humans must await further basic and clinical research but DR3/4 heterozygous or DR4/4 homozygous relatives or both as shown in our study represent a very high-risk cohort for development of autoantibodies by the age of 2 years.
Preliminary data from the diabetes autoimmunity study in the young (DAISY) and Diabetes Prediction and Prevention (DIPP) study suggest, that the results obtained for offspring of parents with Type I diabetes cannot be extrapolated and extended to the general population. In DAISY, no difference was found in the distribution of islet autoantibodies at 9 and 15 months of age among infants with and without Type I diabetes susceptibility genotypes who did not have a parent with diabetes [20] . In the DIPP study, antibody frequency was increased in offspring of the general population selected for Type I diabetes-related HLA-DQB1 alleles but was considerably lower than the risk in our offspring [21] . Other genes could be relevant and their inclusion could be considered in the general population but longer follow-up and higher ascertainment of infants in these studies are needed to allow such conclusions. Therefore, with current knowledge, primary intervention trials aiming to prevent autoimmunity with invasive therapies should be limited to selected groups within children who have a family history of Type I diabetes.
